Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Buck Website

Christopher B. Buck, Ph.D.

Portait Photo of Christopher Buck
Laboratory of Cellular Oncology
Head, Tumor Virus Molecular Biology Section
Investigator
Center for Cancer Research
National Cancer Institute
Building 37, Room 4118
Bethesda, MD 20892-4263
Phone:  
301-594-7060
Fax:  
Fax Number not listed
E-Mail:  
buckc@mail.nih.gov

Biography

Dr. Buck earned a PhD from the Johns Hopkins School of Medicine. His graduate research, in Professor Robert Siliciano's lab, focused on the translation and immunogenicity of the HIV-1 capsid protein Gag. For his graduate work, Dr. Buck received the Alicia Showalter Reynolds Award. In 2001, Dr. Buck began post-doctoral training in the Lab of Cellular Oncology, where he developed systems for producing human papillomavirus (HPV)-based gene transfer vectors (also known as HPV pseudoviruses). His work using HPV vectors has ranged from basic studies of HPV virion structure and morphogenesis to translational research identifying candidate topical microbicides capable of blocking the infectivity of sexually-transmitted HPVs. For his work in these areas, Dr. Buck and his mentors, John Schiller and Doug Lowy, received the 2006 Norman P. Salzman Award. In 2007, Dr. Buck joined the faculty of the NCI's Center for Cancer Research as a tenure-track Investigator.

Research

Although work in the Tumor Virus Molecular Biology Section (TVMBS) has its roots in the molecular biology of human papillomaviruses (HPVs), the lab is now primarily focused on a different family of cancer-causing viruses called the Polyomaviridae. A great majority of healthy adults chronically shed human polyomavirus virions in their urine and from the surface of their skin. At least one skin-dwelling polyomavirus species, Merkel cell polyomavirus, appears to cause a rare but highly lethal form of skin cancer called Merkel cell carcinoma. Work in the TVMBS has uncovered the existence of three additional polyomaviruses (HPyV6, 7, and 10) that are commonly found on human skin.

The organizing focus of work in the lab is the functional biology of viral capsids. HPVs and polyomaviruses have structurally similar non-enveloped icosahedral capsids that are assembled from a single viral protein (L1 for papillomaviruses, VP1 for polyomaviruses). The virions of non-enveloped viruses are dynamic structures that must undergo a range of conformational changes during different stages of the virus life cycle. Virions must be flexible enough to allow encapsidation of the viral genome, yet stable enough to withstand environmental insults encountered during transmission between hosts. Virions must also become pliable enough to release the viral genome upon infection of a host cell. Because each of these steps involves interactions with host cells, the virion must maintain a variety of evolutionarily conserved motifs capable of binding relatively invariant cellular targets. It is a general principle of virology that conserved ''Achilles heel'' motifs in the virion are structurally obscured to prevent recognition by the immune system. Understanding the nature of these conserved sites of virion vulnerability may allow the development of vaccines capable of eliciting cross-neutralizing antibody responses that can protect vaccinees against polyomavirus-induced disease.

Our group has pioneered the development of HPV-based and, more recently, polyomavirus-based gene transfer vectors. These vectors (also known as pseudoviruses) are thought to deliver encapsidated reporter plasmids to the cell nucleus via pathways that resemble the infectious entry of authentic virions. In addition to their utility for studying the mechanics of infectious entry in vitro and in vivo, the reporter vectors have a variety of other applications. For example, recent collaborative projects suggest that HPV vectors may serve as vehicles for genetic vaccines targeting other viral pathogens, such as HIV. The lab has also used reporter vectors to perform analyses of polyomavirus-neutralizing antibody responses among humans. It is conceivable that such serological analyses may help uncover new links between polyomaviruses and human diseases, including cancer.

Most of the lab's current work is focused on two human polyomaviruses, BKV and JCV, that chronically infect the urinary tract of nearly all adults. Although the two viruses aren't known to cause noticeable symptoms in healthy adults, BKV can cause kidney and bladder damage in organ transplant recipients, and JCV can cause brain damage in immunosuppressed patients. The TVMBS is working to develop vaccines against BKV and JCV.

This page was last updated on 11/7/2013.